Colchicine - what a fascinating medicine. From a rheum point of view, interesting to see it play out for secondary prevention coronary artery disease, lot of patients. Great we can share our collective clinical confidence with it with cardiology #ACR23 @US_FDA session @RheumNow https://t.co/Q7zLtyby8l

Are Long-term NSAIDs safe in AS? Ab#0528 #ACR23 @RheumNow 19,775 AS pts vs 59,325 controls. Incidence of 16.9, 13.8 per 1,000 person-yrs, respectively Long-term use of NSAIDs increased risk of CVD in non-AS control (aHR 1.64), but did NOT in AS pts (aHR 1.06)

Ab#498 Does DMARD for PsO and PsA decrease MACE? #ACR23 @RheumNow Retrospective database Israeli study. PsO, PsA on MTX or bDMARD: lower MACE compared to health matched controled (HR 0.45-0.68, p<0.001) Pts on topical Rx had marginally Increased MACE (HR 1.14, p <0.001) https://t.co/0uRgjzYbFp

Systemic anti-inflammatory treatments for PsO and PsA including methotrexate and biologics provided cardioprotective effects Potential cardiovascular benefits of IL-17i and IL-12/23i compared to TNFi @RheumNow #ACR23 Abs#0498 https://t.co/Np7PSNvFd6

Difficult to treat D2T-axSpA (failure > 3 biologics), affects one in five patients exposed to b/tsDMARDs in this national registry. D2T is more common in women, presence of peripheral involvement, psoriasis, depression, Fakih O Abst#0514 #ACR23 @RheumNow https://t.co/OoymZzzQST https://t.co/EpTqS1C61A

Yet another (mostly) reassuring report about lymphoma and DMARDS The skin cancer signal in the CIRT trial was weird; would be worth looking into that in observational studies as well @NamrataRheum #ACR23 Abst0438 @RheumNow https://t.co/Beg8UUe2mn

It seems so simple. We should be able to use proteomics to better pick winners when it comes to b/tsDMARDs in RA. Why is it hard? I guess: - theory ≠ practice - too many other factors - it's too easy not to Yet I hope/believe, one day we'll do better. #ACR23 ABST0427 @RheumNow https://t.co/5VBVp3KOJN

If you're >65 years old & have new RA, you start a DMARD, right? At worst, sometime in the first year? US Medicare data 2008-17 n=33,373 only 30% have a DMARD on file (of which bDMARD <10%) >5% on PNL alone Do we hate old people with RA?😔 @JihaRheum #ACR23 ABST0433 @RheumNow https://t.co/1CUXAh3fi0

Year in Review by Dr. P Seo NORD-STAR trial: ⭐️Abatacept or Certolizumab >> Tociluzumab > triple therapy in tx of 812 early RA patients based on clinical & radiographic results ➡️tx-naive, all got MTX ➡️mod-sev dz activity ➡️randomized to 48 wks therapy #ACR23 @RheumNow https://t.co/vy2uYuyOse